Paul A Grayburn
Overview
Explore the profile of Paul A Grayburn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
251
Citations
6186
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
George T, Squiers J, DiMaio J, Banwait J, Grayburn P, Mack M, et al.
Ann Thorac Surg
. 2025 Feb;
PMID: 39929332
Background: Retrospective studies of patients with ischemic mitral regurgitation(iMR) undergoing coronary artery bypass grafting(CABG) with concomitant mitral valve surgery frequently report improved survival with mitral valve annuloplasty(MVr) over replacement(MVR). However,...
2.
Strom J, Mulvagh S, Porter T, Main M, Grayburn P
Am J Cardiol
. 2024 Dec;
239:95-97.
PMID: 39637929
No abstract available.
3.
Arnold S, Hahn R, Thourani V, Makkar R, Makar M, Sharma R, et al.
J Am Coll Cardiol
. 2024 Oct;
85(3):206-216.
PMID: 39480380
Background: Severe tricuspid regurgitation (TR) often causes substantial impairment in patient-reported health status (ie, symptoms, physical and social function, and quality of life), which may improve with transcatheter tricuspid valve...
4.
Hahn R, Makkar R, Thourani V, Makar M, Sharma R, Haeffele C, et al.
N Engl J Med
. 2024 Oct;
392(2):115-126.
PMID: 39475399
Background: Severe tricuspid regurgitation is associated with disabling symptoms and an increased risk of death. Data regarding outcomes after percutaneous transcatheter tricuspid-valve replacement are needed. Methods: In this international, multicenter...
5.
Hahn R, Makkar R, Makar M, Davidson C, Puthamana J, Zahr F, et al.
JACC Cardiovasc Interv
. 2024 Sep;
17(18):2093-2112.
PMID: 39322362
With the recent approval of the transcatheter EVOQUE tricuspid valve replacement system to treat severe, symptomatic tricuspid regurgitation, there is a need to define the appropriate patient population and anatomical...
6.
Bohra C, Asch F, Lerakis S, Little S, Redfors B, Zhou Z, et al.
Struct Heart
. 2024 Sep;
8(5):100333.
PMID: 39290680
Background: The implications of pulmonary vein (PV) flow patterns in patients with heart failure (HF) and mitral regurgitation (MR) are uncertain. We examined PV flow patterns in the Cardiovascular Outcomes...
7.
Lerakis S, Kini A, Giustino G, Anastasius M, Asch F, Weissman N, et al.
J Soc Cardiovasc Angiogr Interv
. 2024 Aug;
3(5):101345.
PMID: 39132458
Background: Transcatheter edge-to-edge repair (TEER) improved outcomes in patients with heart failure (HF) and severe secondary mitral regurgitation (SMR) compared with guideline-directed medical therapy (GDMT) alone regardless of the severity...
8.
Estevez-Loureiro R, Shah N, Raposeiras-Roubin S, Kotinkaduwa L, Madhavan M, Gray W, et al.
J Soc Cardiovasc Angiogr Interv
. 2024 Aug;
3(2):101227.
PMID: 39132211
Background: Risk scores may identify patients with mitral regurgitation (MR) who are at risk for adverse events, but who may still benefit from transcatheter edge-to-edge repair (TEER). We sought to...
9.
Fortuni F, Grayburn P
JACC Cardiovasc Imaging
. 2024 Jul;
17(9):1041-1043.
PMID: 39001734
No abstract available.
10.
Grayburn P, Kodali S, Hahn R, Lurz P, Thourani V, Kozorovitsky E, et al.
Am J Cardiol
. 2024 Jun;
225:171-177.
PMID: 38897265
Severe tricuspid regurgitation remains largely undertreated given limited treatment options. Transcatheter tricuspid valve interventions have emerged as a promising therapy for these patients, and the TRISCEND II pivotal trial is...